DEMANT Demant A/S

Demant A/S: Managers' transactions

Demant A/S: Managers' transactions

Company announcement no 2020-092 July 2020

Transactions with Demant A/S shares by senior executives and closely related parties

Notification pursuant to article 19, sub-article 2a, of the Market Abuse Regulation:

1.Details of the person discharging managerial responsibilities/person closely associated
a)NameAnja Madsen
2.Reason for the notification
a)Position/statusMember of the Board of Directors
b)Initial notification/amendmentInitial notification
3)Details of the issuer, emission allowance market participant, auction platform, auctioneer

or auction monitor
a)NameDemant A/S
b)LEI213800RM6L9LN78BVA56
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial

instrument, type of instrument



 



Identication code
Shares



 



 



DK0060738599
b)Nature of the transactionPurchase
c)Price(s) and volume(s)Price  Volume

DKK 176.20  751 shares

DKK 176.00  100 shares
d)Aggregated information:

- Aggregated volume

- Price
 



851 shares

DKK 176.37
e)Date of the transaction29 June 2020
f)Place of the transactionNasdaq Copenhagen A/S

* * * * * * *

Further information:

Christian Lange, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communication and Relations

Phone

 

 

Attachment

EN
02/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Demant A/S

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

3% organic is weak, but underlying is fine

Q1: '24 low point, meagre 3% growth pushes market share lower. Demant doing well overall beyond the 3% figure. HOLD, TP 340 (350) on 3% underlying '24e EBIT cut.

Rune Majlund Dahl
  • Rune Majlund Dahl

Demant (Buy, TP: DKK400.00) - Better quarters should lie ahead

Q1 organic growth was a soft c3% YOY on tough comparables, reflecting growth of c4% for Hearing Aids and c7% for Diagnostics, but a weak c0% for Hearing Care due to slowing momentum in France. We expect 2024 to be back-end loaded and driven by Oticon Intent. The 2024 guidance was unchanged for key lines, including organic growth of 4–8%, EBIT of DKK4.6bn–5.0bn, and share buybacks of DKK2.0bn+. We reiterate our BUY and DKK400 target price.

Oliver Metzger
  • Oliver Metzger

Demant A/S : Slower start to 2024, weaker dynamics in France, UK and C...

>Q1 review – slower organic growth leads to miss on sales forecast - Demant’s Q1 revenues of DKK 5,423m (-1.5% y-o-y,) were driven by organic growth of 3% (vs ODDO BHF 6.2%/consensus 4.7%) and were -3%-2% vs ODDO BHF/consensus. The Communication business is excluded from the operating development as the asset is booked as discontinued operation. No bottom line was reported on a quarterly basis.Hearing aids impacted by flat growth in Europe - Hearing a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch